Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.

Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS.

Oncotarget. 2017 Mar 28;8(13):20925-20938. doi: 10.18632/oncotarget.14995.

2.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review.

PMID:
27988492
3.

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment.

Ferraldeschi R, Newman WG.

Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122-1138. Review.

4.

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.

Lin G, Zhang K, Yi L, Han Y, Xie J, Li J.

PLoS One. 2016 Sep 7;11(9):e0162361. doi: 10.1371/journal.pone.0162361. eCollection 2016. Erratum in: PLoS One. 2016 Dec 1;11(12 ):e0167740.

5.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

6.

Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Morgan MM, Johnson BP, Livingston MK, Schuler LA, Alarid ET, Sung KE, Beebe DJ.

Pharmacol Ther. 2016 Sep;165:79-92. doi: 10.1016/j.pharmthera.2016.05.007. Epub 2016 May 21. Review.

PMID:
27218886
7.

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.

Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S.

Onco Targets Ther. 2016 Apr 12;9:2121-9. doi: 10.2147/OTT.S100905. eCollection 2016.

8.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3. Review.

9.

Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.

Hayes EL, Lewis-Wambi JS.

Breast Cancer Res. 2015 Mar 17;17:40. doi: 10.1186/s13058-015-0542-y. Review.

10.

Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia.

Tang KF, Zhao YL, Ding SS, Wu QF, Wang XY, Shi JQ, Sun F, Xing JP.

J Zhejiang Univ Sci B. 2015 Mar;16(3):191-7. doi: 10.1631/jzus.B1400282.

11.

Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.

Zhang X, Pu Z, Ge J, Shen J, Yuan X, Xie H.

Med Sci Monit. 2015 Feb 21;21:563-9. doi: 10.12659/MSM.893473.

12.

Prognostic and predictive biomarkers: tools in personalized oncology.

Nalejska E, Mączyńska E, Lewandowska MA.

Mol Diagn Ther. 2014 Jun;18(3):273-84. doi: 10.1007/s40291-013-0077-9. Review.

13.

Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Cronin-Fenton DP, Damkier P, Lash TL.

Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168. Review.

14.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

15.

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.

Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D.

Pharmgenomics Pers Med. 2013 Aug 26;6:93-8. doi: 10.2147/PGPM.S44006. eCollection 2013.

16.

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen.

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C.

Pharmgenomics Pers Med. 2013 May 24;6:37-48. doi: 10.2147/PGPM.S42330. Print 2013.

17.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

18.

Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.

Vianna-Jorge R, Festa-Vasconcellos JS, Goulart-Citrangulo SM, Leite MS.

Front Genet. 2013 Jan 22;3:329. doi: 10.3389/fgene.2012.00329. eCollection 2012.

19.

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients.

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C.

Pharmgenomics Pers Med. 2012;5:149-53. doi: 10.2147/PGPM.S32160. Epub 2012 Oct 17.

20.

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.

Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J.

Br J Cancer. 2012 Jul 10;107(2):230-3. doi: 10.1038/bjc.2012.278. Epub 2012 Jun 26.

Supplemental Content

Support Center